Epidermal growth factor receptor (EGFR) and histone deacetylase 3 (HDAC3) synergistically drive malignant progression in triple-negative breast cancer (TNBC). In this study, a series of N-benzyl-2-fluorobenzamide derivatives (11-43) were identified as EGFR/HDAC3 dual-target inhibitors. Among them, compound 38 exhibited the most promising activity, with IC₅₀ values of 20.34 nM and 1.09 μM against EGFR and HDAC3, respectively. Molecular modeling revealed that the 2-fluorobenzamide moiety of 38 chelates with Zn2+ in the active channel of HDAC3, while the 4-fluorobenzyl group occupies the ATP-binding pocket of EGFR, exercising a dual-target binding function. In vitro experiments demonstrated that 38 exhibited superior anti-proliferative activity (IC₅₀ = 1.98 μM) against MDA-MB-231 cells compared to chidamide (IC₅₀ = 24.37 μM), inducing 74.15 % inhibition of cell migration and 57.4 % late-stage apoptosis. In vivo studies revealed that 38 (30 mg/kg/day) suppressed tumor growth by 34.78 % without significant toxicity. Collectively, 38 represents a novel dual EGFR/HDAC3 inhibitor that shows promising potential for providing new therapeutic insights into TNBC treatment.
{"title":"Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer.","authors":"Gong-Hui Ge, Shuai Guo, Ting-Ting Li, Yan-Ping Wang, Li-Rong Liu, Wen-Hui Yu, Hao Hu, Yi-Meng Zheng, Jing-Han Yan, Ying-Hao Sun, Jing-Wei Liang, Fan-Hao Meng, Ting-Jian Zhang","doi":"10.1016/j.bmcl.2025.130362","DOIUrl":"10.1016/j.bmcl.2025.130362","url":null,"abstract":"<p><p>Epidermal growth factor receptor (EGFR) and histone deacetylase 3 (HDAC3) synergistically drive malignant progression in triple-negative breast cancer (TNBC). In this study, a series of N-benzyl-2-fluorobenzamide derivatives (11-43) were identified as EGFR/HDAC3 dual-target inhibitors. Among them, compound 38 exhibited the most promising activity, with IC₅₀ values of 20.34 nM and 1.09 μM against EGFR and HDAC3, respectively. Molecular modeling revealed that the 2-fluorobenzamide moiety of 38 chelates with Zn<sup>2+</sup> in the active channel of HDAC3, while the 4-fluorobenzyl group occupies the ATP-binding pocket of EGFR, exercising a dual-target binding function. In vitro experiments demonstrated that 38 exhibited superior anti-proliferative activity (IC₅₀ = 1.98 μM) against MDA-MB-231 cells compared to chidamide (IC₅₀ = 24.37 μM), inducing 74.15 % inhibition of cell migration and 57.4 % late-stage apoptosis. In vivo studies revealed that 38 (30 mg/kg/day) suppressed tumor growth by 34.78 % without significant toxicity. Collectively, 38 represents a novel dual EGFR/HDAC3 inhibitor that shows promising potential for providing new therapeutic insights into TNBC treatment.</p>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":" ","pages":"130362"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144787866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
12-O-alkyl, acyl, and phenylcarbamoyl, and 11-bromo-7-oxo analogues were prepared from pisiferic acid from Chamaecyparis pisifera, and evaluated anti-adipogenic activity. Among them, pisiferic acid and methyl 12-O-phenylcarbamoylpisiferic acid methyl ester showed relatively high anti-adipogenic effect in 3T3-L1 adipocytes and should be thought to be potential candidates for anti-obesity drug.
以松香豆酸为原料制备了12- o-烷基、酰基、苯基氨基甲酰和11-溴-7-氧类似物,并对其抗脂肪活性进行了评价。其中,pisiferic酸和甲基12- o -苯基氨基甲酰pisiferic酸甲酯在3T3-L1脂肪细胞中表现出较高的抗脂肪作用,应被认为是抗肥胖药物的潜在候选者。
{"title":"Synthesis of pisiferic acid analogues and their anti-adipogenic effect in 3T3-L1 adipocytes.","authors":"Ayako Oshika, Sayumi Ono, Haruka Iwano, Manami Toda, Risa Obayashi, Yuna Takagi, Mako Higashitani, Satomi Fukuoka, Miduki Furukawa, Karen Yagami, Rena Okamura, Natsumi Futoi, Hiroki Yoshioka, Reiko Yano, Koji Yoshida, Hyun-Sun Park, Tomoyo Hasuda, Yukio Hitotsuyanagi, Koichi Takeya, Tomohiro Yamaguchi, Yutaka Aoyagi","doi":"10.1016/j.bmcl.2025.130354","DOIUrl":"10.1016/j.bmcl.2025.130354","url":null,"abstract":"<p><p>12-O-alkyl, acyl, and phenylcarbamoyl, and 11-bromo-7-oxo analogues were prepared from pisiferic acid from Chamaecyparis pisifera, and evaluated anti-adipogenic activity. Among them, pisiferic acid and methyl 12-O-phenylcarbamoylpisiferic acid methyl ester showed relatively high anti-adipogenic effect in 3T3-L1 adipocytes and should be thought to be potential candidates for anti-obesity drug.</p>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":" ","pages":"130354"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ulcerative colitis (UC) is considered as one of the most prevalent inflammatory bowel diseases (IBDs), which increases risks for colectomy and colorectal cancer. However, due to moderate efficiency and potential side effects of first-line drugs, it is desirable to develop more efficient anti-UC agents. The natural peptide Melittin, which is the main active ingredient of bee venom, is considered as a potential scaffold for the development of anti-UC drugs. Nevertheless, as a linear amphipathic peptide, Melittin could be degraded by various proteases, suffering from poor stability and short half-lives. Previous studies on structural optimization or the potential of Melittin-derived peptides for anti-UC applications still remain limited. In this study, the stability-guided optimization and anti-UC evaluation were conducted on Melittin. The robust synthetic strategy, in vivo anti-UC activity, and anti-inflammatory mechanism were investigated. Compared with Melittin, the derived peptides represented by PCJ-675 were found to exhibit improved proteolytic stability. In the dextran sulfate sodium (DSS)-induced UC mice model, PCJ-675 could significantly alleviate both colon shortening and suppress inflammation symptoms in colon tissue. The western blotting and biochemical indicators suggested that the oral administration of PCJ-675 could protect the colon in colitis mice by inhibiting both the excessive activation of the inflammation-related TLR4/NF-κB pathway and the overexpression of pro-inflammatory cytokines (eg, IL-1β, IL-6, and TNF-α). Collectively, this study not only stablished robust strategies to improve the stability and anti-UC potential of Melittin, but also provided valuable references for the future development of natural cytotoxic peptides based anti-UC agents.
{"title":"Efficient synthesis, stability-guided optimization and anti-ulcerative colitis evaluation of bee venom peptide melittin.","authors":"Cheng-Jian Pang, Jing-Fang Yao, Qiu-Lan Lv, Li-Ze Zhang, Qian-Yao Yu, Li Zeng, Yun-Kun Qi","doi":"10.1016/j.bmcl.2025.130357","DOIUrl":"10.1016/j.bmcl.2025.130357","url":null,"abstract":"<p><p>Ulcerative colitis (UC) is considered as one of the most prevalent inflammatory bowel diseases (IBDs), which increases risks for colectomy and colorectal cancer. However, due to moderate efficiency and potential side effects of first-line drugs, it is desirable to develop more efficient anti-UC agents. The natural peptide Melittin, which is the main active ingredient of bee venom, is considered as a potential scaffold for the development of anti-UC drugs. Nevertheless, as a linear amphipathic peptide, Melittin could be degraded by various proteases, suffering from poor stability and short half-lives. Previous studies on structural optimization or the potential of Melittin-derived peptides for anti-UC applications still remain limited. In this study, the stability-guided optimization and anti-UC evaluation were conducted on Melittin. The robust synthetic strategy, in vivo anti-UC activity, and anti-inflammatory mechanism were investigated. Compared with Melittin, the derived peptides represented by PCJ-675 were found to exhibit improved proteolytic stability. In the dextran sulfate sodium (DSS)-induced UC mice model, PCJ-675 could significantly alleviate both colon shortening and suppress inflammation symptoms in colon tissue. The western blotting and biochemical indicators suggested that the oral administration of PCJ-675 could protect the colon in colitis mice by inhibiting both the excessive activation of the inflammation-related TLR4/NF-κB pathway and the overexpression of pro-inflammatory cytokines (eg, IL-1β, IL-6, and TNF-α). Collectively, this study not only stablished robust strategies to improve the stability and anti-UC potential of Melittin, but also provided valuable references for the future development of natural cytotoxic peptides based anti-UC agents.</p>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":" ","pages":"130357"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ginsenosides, the pharmacologically active components of Panax ginseng, are widely used in herbal medicine and reportedly exert diverse biological effects, including anticancer, anti-inflammatory, and neuroprotective activities. However, their pharmacological mechanisms remain poorly understood, owing to the lack of chemical probes suitable for in vivo analyses. Herein, we report the development of a 11C radiolabeling of 20(S)-protopanaxadiol (PPD), a major aglycone-type active ginsenoside metabolite, for positron emission tomography (PET) imaging. For the 11C labeling of PPD, we focused on the terminal vinyl methyl group of the dammarane-type triterpene backbone, a common structural element found in ginsenosides. A boronic precursor applicable for rapid 11C-methylation was efficiently synthesized via steps focusing on the controlled cross-metathesis of an internal olefin. The subsequent Pd(0)-mediated rapid 11C-methylation was conducted in N,N-dimethylformamide (DMF)/H₂O using [Pd₂(dba)₃], P(o-tolyl)₃, and sodium ascorbate, which functioned as a base and a radical scavenger. After formulation, the resulting [11C]PPD was obtained in a decay-corrected radiochemical yield of 15 ± 2 % (n = 3), with a total radioactivity of 1.0 ± 0.3 GBq (n = 3) and molar activity of 124 ± 7 GBq/μmol (n = 3). Radiochemical purity was ≥99 %, and the total synthesis time was 29 min. Using [11C]PPD, PET imaging of the brains of healthy rats and abdomens of healthy mice demonstrated low brain uptake and pronouncedly clear hepatobiliary excretion of radiolabeled species. These findings may provide a foundation for the general labeling of ginsenoside structures with 11C radioisotopes, thereby enabling systematic in vivo pharmacokinetic analyses of PPD derivatives to advance ginsenoside-based drug development.
{"title":"<sup>11</sup>C-labeling of 20(S)-protopanaxadiol, an aglycon of ginsenoside, based on the use of Pd(0)-mediated rapid C-[<sup>11</sup>C]methylation of boronic precursors.","authors":"Yoshiki Ooshima, Hiroko Koyama, Aya Ogata, Hiroshi Ikenuma, Takashi Yamada, Hiroyuki Kojima, Takashi Kato, Yasuyuki Kimura, Masaaki Suzuki","doi":"10.1016/j.bmcl.2025.130356","DOIUrl":"10.1016/j.bmcl.2025.130356","url":null,"abstract":"<p><p>Ginsenosides, the pharmacologically active components of Panax ginseng, are widely used in herbal medicine and reportedly exert diverse biological effects, including anticancer, anti-inflammatory, and neuroprotective activities. However, their pharmacological mechanisms remain poorly understood, owing to the lack of chemical probes suitable for in vivo analyses. Herein, we report the development of a <sup>11</sup>C radiolabeling of 20(S)-protopanaxadiol (PPD), a major aglycone-type active ginsenoside metabolite, for positron emission tomography (PET) imaging. For the <sup>11</sup>C labeling of PPD, we focused on the terminal vinyl methyl group of the dammarane-type triterpene backbone, a common structural element found in ginsenosides. A boronic precursor applicable for rapid <sup>11</sup>C-methylation was efficiently synthesized via steps focusing on the controlled cross-metathesis of an internal olefin. The subsequent Pd(0)-mediated rapid <sup>11</sup>C-methylation was conducted in N,N-dimethylformamide (DMF)/H₂O using [Pd₂(dba)₃], P(o-tolyl)₃, and sodium ascorbate, which functioned as a base and a radical scavenger. After formulation, the resulting [<sup>11</sup>C]PPD was obtained in a decay-corrected radiochemical yield of 15 ± 2 % (n = 3), with a total radioactivity of 1.0 ± 0.3 GBq (n = 3) and molar activity of 124 ± 7 GBq/μmol (n = 3). Radiochemical purity was ≥99 %, and the total synthesis time was 29 min. Using [<sup>11</sup>C]PPD, PET imaging of the brains of healthy rats and abdomens of healthy mice demonstrated low brain uptake and pronouncedly clear hepatobiliary excretion of radiolabeled species. These findings may provide a foundation for the general labeling of ginsenoside structures with <sup>11</sup>C radioisotopes, thereby enabling systematic in vivo pharmacokinetic analyses of PPD derivatives to advance ginsenoside-based drug development.</p>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":" ","pages":"130356"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-28DOI: 10.1016/j.bmcl.2025.130489
Xudong Pang , Dawei Cui , Ruifeng Liu , Binhua Lv , Cheng-Yun Wang
NASH represents an increasingly prevalent chronic liver disease, and TZDs are investigated as a potential therapeutic strategy. However, the inherent enolic structure of TZDs leads to enantiomeric instability and racemization, often requiring their use as racemic mixtures. We here report the development of a novel TZD-derivative, 9, in which deuterium incorporation at the chiral center was strategically employed to enhance stereoisomeric stability while maintaining the desired pharmacological profile. In vitro, compound 9 displayed robust activity, with an EC50 of 0.32 ± 0.04 μM in HEK293 cells. Pharmacokinetic analysis revealed a Cmax of 1693 ± 339 ng/mL and an AUC0-24h of 8711 ± 871 ng∙h/mL. Furthermore, compound 9 demonstrated superior therapeutic efficacy in a mouse model of NASH. These findings suggest that the compound 9 represents a promising therapeutic candidate for NASH.
{"title":"Exploring the therapeutic potential of deuterated PPARγ agonists for NASH","authors":"Xudong Pang , Dawei Cui , Ruifeng Liu , Binhua Lv , Cheng-Yun Wang","doi":"10.1016/j.bmcl.2025.130489","DOIUrl":"10.1016/j.bmcl.2025.130489","url":null,"abstract":"<div><div>NASH represents an increasingly prevalent chronic liver disease, and TZDs are investigated as a potential therapeutic strategy. However, the inherent enolic structure of TZDs leads to enantiomeric instability and racemization, often requiring their use as racemic mixtures. We here report the development of a novel TZD-derivative, <strong>9</strong>, in which deuterium incorporation at the chiral center was strategically employed to enhance stereoisomeric stability while maintaining the desired pharmacological profile. In vitro, compound <strong>9</strong> displayed robust activity, with an EC<sub>50</sub> of 0.32 ± 0.04 μM in HEK293 cells. Pharmacokinetic analysis revealed a C<sub>max</sub> of 1693 ± 339 ng/mL and an AUC<sub>0-24h</sub> of 8711 ± 871 ng∙h/mL. Furthermore, compound <strong>9</strong> demonstrated superior therapeutic efficacy in a mouse model of NASH. These findings suggest that the compound <strong>9</strong> represents a promising therapeutic candidate for NASH.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"132 ","pages":"Article 130489"},"PeriodicalIF":2.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145647004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-27DOI: 10.1016/j.bmcl.2025.130482
Yanhui Yi , Yupei Sun , Xiangyang Zhang , Jianzeng Xin , Feng Zhao , Wei Zhu , Sheng Liu
Liver cancer represents a major global health challenge, significantly impacting populations both in China and worldwide. Alpinetin (ALP), extracted from the ginger plant cardamom, has been shown to possess significant anti-liver cancer activity. However, its solubility and mechanism of action remain unclear, hindering its further development and application. Heat shock protein 70 (HSP70) has been proven to be a potential target for the treatment of liver cancer. Based on rational drug design principles, ALP was conjugated with specific pharmacophores through oxime linkages to yield novel compounds, aiming to reduce toxicity and enhanced activity. Thus, representative compounds 1a and 1b were obtained. Then, the preliminary mechanism of action was further investigated. Western blot analysis results indicate that compounds 1a and 1b could inhibit the expression of HSP70 protein in HepG2 liver cancer cells. Cell apoptosis data indicate that the synthesized compounds exert anticancer activity by inducing apoptosis. Therefore, this study suggests that ALP and its derivatives may become promising drugs for exerting anti liver cancer effects by regulating the expression of HSP70 protein.
{"title":"Design, synthesis, and activity evaluation of alpinetin derivatives as potential anti-liver cancer drugs","authors":"Yanhui Yi , Yupei Sun , Xiangyang Zhang , Jianzeng Xin , Feng Zhao , Wei Zhu , Sheng Liu","doi":"10.1016/j.bmcl.2025.130482","DOIUrl":"10.1016/j.bmcl.2025.130482","url":null,"abstract":"<div><div>Liver cancer represents a major global health challenge, significantly impacting populations both in China and worldwide. Alpinetin (ALP), extracted from the ginger plant cardamom, has been shown to possess significant anti-liver cancer activity. However, its solubility and mechanism of action remain unclear, hindering its further development and application. Heat shock protein 70 (HSP70) has been proven to be a potential target for the treatment of liver cancer. Based on rational drug design principles, ALP was conjugated with specific pharmacophores through oxime linkages to yield novel compounds, aiming to reduce toxicity and enhanced activity. Thus, representative compounds 1a and 1b were obtained. Then, the preliminary mechanism of action was further investigated. Western blot analysis results indicate that compounds 1a and 1b could inhibit the expression of HSP70 protein in HepG2 liver cancer cells. Cell apoptosis data indicate that the synthesized compounds exert anticancer activity by inducing apoptosis. Therefore, this study suggests that ALP and its derivatives may become promising drugs for exerting anti liver cancer effects by regulating the expression of HSP70 protein.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"132 ","pages":"Article 130482"},"PeriodicalIF":2.2,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145627313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer maintains to be a major worldwide health epidemic, and despite breakthroughs in targeted agents, immunotherapy, chemotherapy, and surgery, considerable limitations persist. These comprise therapeutic resistance, dose-limiting toxicities, late diagnosis, and microenvironmental barriers, including hypoxia and poor perfusion. The spatiotemporally regulated, locally activated cytotoxicity that photodynamic therapy (PDT) and sonodynamic therapy (SDT) provide has made them appealing substitutes. They may also be used in conjunction with immunotherapy and imaging. SDT uses ultrasound to allow for deeper penetration and partial oxygen independence, whereas PDT uses light to activate photosensitisers. Both approaches produce radical intermediates and reactive oxygen species (ROS), which harm vital biomolecules and activate several pathways leading to programmed cell death, hence decreasing the probability of resistance. However, SDT necessitates the optimisation of acoustic parameters and verified clinical protocols, while PDT is limited by oxygen reliance and poor light penetration. Transition metal complexes, especially those of iridium (III) and rhenium (I), offer special benefits for PDT and SDT because of their intrinsic luminescence, effective triplet-state creation, high spin–orbit coupling, and variable photophysical characteristics. Their translational potential is being advanced by rational design tactics such as theranostic pairing, red/NIR and two-photon activation, nanocarrier integration, and Type I biasing for hypoxia tolerance. With continuous attempts to standardise dosimetry and sensitiser design, SDT is still in the early phases of evaluation, whereas PDT is clinically established. This study highlights Ir and Re complexes as adaptable next-generation sensitisers that could broaden the therapeutic reach of externally activated cancer medicines by synthesising molecular insights, representative chemical classes, and translational obstacles.
{"title":"Iridium and rhenium complexes in photodynamic and sonodynamic therapy: mechanistic insights and therapeutic potential","authors":"Sreejani Ghosh , Rinku Chakrabarty , Priyankar Paira","doi":"10.1016/j.bmcl.2025.130479","DOIUrl":"10.1016/j.bmcl.2025.130479","url":null,"abstract":"<div><div>Cancer maintains to be a major worldwide health epidemic, and despite breakthroughs in targeted agents, immunotherapy, chemotherapy, and surgery, considerable limitations persist. These comprise therapeutic resistance, dose-limiting toxicities, late diagnosis, and microenvironmental barriers, including hypoxia and poor perfusion. The spatiotemporally regulated, locally activated cytotoxicity that photodynamic therapy (PDT) and sonodynamic therapy (SDT) provide has made them appealing substitutes. They may also be used in conjunction with immunotherapy and imaging. SDT uses ultrasound to allow for deeper penetration and partial oxygen independence, whereas PDT uses light to activate photosensitisers. Both approaches produce radical intermediates and reactive oxygen species (ROS), which harm vital biomolecules and activate several pathways leading to programmed cell death, hence decreasing the probability of resistance. However, SDT necessitates the optimisation of acoustic parameters and verified clinical protocols, while PDT is limited by oxygen reliance and poor light penetration. Transition metal complexes, especially those of iridium (III) and rhenium (I), offer special benefits for PDT and SDT because of their intrinsic luminescence, effective triplet-state creation, high spin–orbit coupling, and variable photophysical characteristics. Their translational potential is being advanced by rational design tactics such as theranostic pairing, red/NIR and two-photon activation, nanocarrier integration, and Type I biasing for hypoxia tolerance. With continuous attempts to standardise dosimetry and sensitiser design, SDT is still in the early phases of evaluation, whereas PDT is clinically established. This study highlights Ir and Re complexes as adaptable next-generation sensitisers that could broaden the therapeutic reach of externally activated cancer medicines by synthesising molecular insights, representative chemical classes, and translational obstacles.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"132 ","pages":"Article 130479"},"PeriodicalIF":2.2,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145627295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-21DOI: 10.1016/j.bmcl.2025.130481
Wei Fan , Meina Li , Yeming Wang
In this study, 2,4,6-trisubstituted pyridine derivative Z-001 containing adamantyl moiety was designed through the hybridization strategy of LXH254 and adamantane. A new and effective synthetic route was established to achieve the synthesis of Z-001 through four step reactions, starting from commercially available 3-bromo-4-methylaniline and (2,6-dichloropyridin-4-yl) boronic acid. Besides, Z-001 was evaluated inhibitory activity against B-RAF kinase with IC50 value of 37.80 nM by ADP-Glo kinase assay, and it was found that Z-001 was a more potent B-RAF inhibitor than Vemurafinib (IC50 = 78.52 nM). Furthermore, molecular docking simulations showed that Z-001 bound to DFG-out/C-helix-in conformation in the B-RAF kinase, and formed three hydrogen bonds with GLU501, ASP594 and CYS532, respectively. It was worth noting that the adamantane alcohol of Z-001 was very suitable for matching the cavities near the solvent exposed region, which was filled with adamantyl moiety and effectively utilized in the docking model. The binding mode between Z-001 and B-RAF kinase provided a reasonable explanation for Z-001 as a potential B-RAF kinase inhibitor.
本研究通过LXH254与金刚烷的杂化策略,设计了含有金刚烷片段的2,4,6-三取代吡啶衍生物Z-001。以市售的3-溴-4-甲基苯胺和(2,6-二氯吡啶-4-基)硼酸为原料,通过四步反应合成了Z-001。此外,通过ADP-Glo激酶试验评估Z-001对B-RAF激酶的抑制活性,IC50值为37.80 nM,发现Z-001比Vemurafinib更有效(IC50 = 78.52 nM)。此外,分子对接模拟表明,Z-001在B-RAF激酶中结合到DFG-out/ c -螺旋-in构象,并分别与GLU501、ASP594和CYS532形成3个氢键。值得注意的是,Z-001的金刚烷醇非常适合匹配溶剂暴露区附近的空腔,其中充满金刚烷基部分,在对接模型中得到了有效的利用。Z-001与B-RAF激酶的结合模式为Z-001作为潜在的B-RAF激酶抑制剂提供了合理的解释。
{"title":"LXH254 hybrid with adamantane: synthesis and in vitro evaluation of 2,4,6-trisubstituted pyridine derivative Z-001 containing adamantyl moiety as a novel B-RAF inhibitor","authors":"Wei Fan , Meina Li , Yeming Wang","doi":"10.1016/j.bmcl.2025.130481","DOIUrl":"10.1016/j.bmcl.2025.130481","url":null,"abstract":"<div><div>In this study, 2,4,6-trisubstituted pyridine derivative <strong>Z-001</strong> containing adamantyl moiety was designed through the hybridization strategy of LXH254 and adamantane. A new and effective synthetic route was established to achieve the synthesis of <strong>Z-001</strong> through four step reactions, starting from commercially available 3-bromo-4-methylaniline and (2,6-dichloropyridin-4-yl) boronic acid. Besides, <strong>Z-001</strong> was evaluated inhibitory activity against B-RAF kinase with IC<sub>50</sub> value of 37.80 nM by ADP-Glo kinase assay, and it was found that <strong>Z-001</strong> was a more potent B-RAF inhibitor than Vemurafinib (IC<sub>50</sub> = 78.52 nM). Furthermore, molecular docking simulations showed that <strong>Z-001</strong> bound to DFG-out/C-helix-in conformation in the B-RAF kinase, and formed three hydrogen bonds with GLU501, ASP594 and CYS532, respectively. It was worth noting that the adamantane alcohol of <strong>Z-001</strong> was very suitable for matching the cavities near the solvent exposed region, which was filled with adamantyl moiety and effectively utilized in the docking model. The binding mode between <strong>Z-001</strong> and B-RAF kinase provided a reasonable explanation for <strong>Z-001</strong> as a potential B-RAF kinase inhibitor.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130481"},"PeriodicalIF":2.2,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145585582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-20DOI: 10.1016/j.bmcl.2025.130480
Jiyun Zhu , Sara Gutkin , Shiyu Chen , Shih-Po Su , Hai Phan , Doron Shabat , Matthew Bogyo
The cysteine cathepsins are a family of proteases that are widely expressed in diverse cell types. However, because their activity is highly upregulated at sites of inflammation, they are ideal targets for imaging a range of disease pathologies including cancer, atherosclerosis, fibrosis and others. While significant advances have been made in generation of activatable ‘smart’ probes for cathepsin activity, virtually all of these agents use fluorescent reporters which require a laser light source to induce a signal from the probe. We describe here the development and application of chemiluminescent probes for imaging cysteine cathepsin activity in cells and tissues. These probes provide rapid signal generation with low background in cells and tissues without the need for a light source. We demonstrate that a cathepsin probe containing an optimal peptide sequence can be used topically to detect activity in tumor tissues, demonstrating the potential value of this approach for real-time diagnosis of cancer as well as other conditions involving inflammation.
{"title":"Chemiluminescent probes for imaging cysteine cathepsin activity","authors":"Jiyun Zhu , Sara Gutkin , Shiyu Chen , Shih-Po Su , Hai Phan , Doron Shabat , Matthew Bogyo","doi":"10.1016/j.bmcl.2025.130480","DOIUrl":"10.1016/j.bmcl.2025.130480","url":null,"abstract":"<div><div>The cysteine cathepsins are a family of proteases that are widely expressed in diverse cell types. However, because their activity is highly upregulated at sites of inflammation, they are ideal targets for imaging a range of disease pathologies including cancer, atherosclerosis, fibrosis and others. While significant advances have been made in generation of activatable ‘smart’ probes for cathepsin activity, virtually all of these agents use fluorescent reporters which require a laser light source to induce a signal from the probe. We describe here the development and application of chemiluminescent probes for imaging cysteine cathepsin activity in cells and tissues. These probes provide rapid signal generation with low background in cells and tissues without the need for a light source. We demonstrate that a cathepsin probe containing an optimal peptide sequence can be used topically to detect activity in tumor tissues, demonstrating the potential value of this approach for real-time diagnosis of cancer as well as other conditions involving inflammation.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"132 ","pages":"Article 130480"},"PeriodicalIF":2.2,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145581582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The inhibition of hypoxia-inducible factor prolyl hydroxylase domain proteins (HIF-PHDs) represents a promising strategy for treating renal anemia. We identified a hydroxypyrimidine core with HIF-PHD inhibitory activity based on a fragment-based drug discovery strategy using various X-ray crystal structures of the HIF-PHD2 domain in complex with a compound. We discovered brand-new amino succinic acid scaffolds by combining the structural information on the crystal structure complexed with 6-acetamide nicotinic acid. DS79540454 exhibits high enzyme inhibitory activity equivalent to that of DS-1093a, which has advanced to clinical trials.
{"title":"Discovery of DS79540454 via fragment-based drug discovery strategy: New scaffolds of hypoxia-inducible factor prolyl hydroxylase inhibitor","authors":"Takeshi Fukuda, Tatsuya Nishi, Takashi Ishiyama, Ryoko Kitazawa, Ken Ishii, Shinichi Takahashi, Yuki Kawabata, Kyoji Yamaguchi, Daichi Baba, Shuichiro Ito, Naoki Tanaka","doi":"10.1016/j.bmcl.2025.130476","DOIUrl":"10.1016/j.bmcl.2025.130476","url":null,"abstract":"<div><div>The inhibition of hypoxia-inducible factor prolyl hydroxylase domain proteins (HIF-PHDs) represents a promising strategy for treating renal anemia. We identified a hydroxypyrimidine core with HIF-PHD inhibitory activity based on a fragment-based drug discovery strategy using various X-ray crystal structures of the HIF-PHD2 domain in complex with a compound. We discovered brand-new amino succinic acid scaffolds by combining the structural information on the crystal structure complexed with 6-acetamide nicotinic acid. DS79540454 exhibits high enzyme inhibitory activity equivalent to that of DS-1093a, which has advanced to clinical trials.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130476"},"PeriodicalIF":2.2,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145561929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}